Ali Behbahani Insider Trading Transactions
Get free email notifications about insider trading for Ali Behbahani.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ali Behbahani. Ali Behbahani is 10% Owner in Marker Therapeutics, Inc. ($MRKR) and Director in NEVRO CORP ($NVRO) and Director in GENOCEA BIOSCIENCES, INC. ($GNCA) and 10% Owner in Regulus Therapeutics Inc. ($RGLS) and 10% Owner in Trevi Therapeutics, Inc. ($TRVI) and Director in Adaptimmune Therapeutics PLC ($ADAP) and 10% Owner in Metacrine, Inc. ($MTCR) and Director in CRISPR Therapeutics AG ($CRSP) and Director in Black Diamond Therapeutics, Inc. ($BDTX) and Director in Oyster Point Pharma, Inc. ($OYST) and 10% Owner in Akouos, Inc. ($AKUS) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and Director in Nkarta, Inc. ($NKTX).
Latest Insider Trading Transactions of Ali Behbahani
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADAP, AKUS, BDTX, CRSP, GNCA, MRKR, MTCR, MIRM, NVRO, NKTX, OYST, RGLS, TRVI
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 22 2021 | BDTX | Black Diamond Ther ... | Behbahani Ali | Director | Grant | A | 24.01 | 547 | 13,133 | 547 | 0 to 547 |
Mar 18 2021 | MRKR | Marker Therapeutic ... | Behbahani Ali | 10% Owner | Buy | P | 1.75 | 5,714,285 | 9,999,999 | 10,714,285 | 5 M to 10.7 M (+114.29 %) |
Dec 07 2020 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Option Exercise | P | 0.00 | 258,707 | 0 | 258,707 | |
Dec 07 2020 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Option Exercise | P | 0.75 | 5,239,254 | 3,910,579 | 5,239,254 | |
Dec 07 2020 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Buy | P | 0.62 | 4,398,602 | 2,735,930 | 6,451,056 | 2.1 M to 6.5 M (+214.31 %) |
Sep 22 2020 | MTCR | Metacrine, Inc. | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 332,964 | 0 | 0 | |
Sep 22 2020 | MTCR | Metacrine, Inc. | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 1,958,333 | 0 | 0 | |
Sep 22 2020 | MTCR | Metacrine, Inc. | Behbahani Ali | 10% Owner | Buy | P | 13.00 | 769,230 | 9,999,990 | 3,060,527 | 2.3 M to 3.1 M (+33.57 %) |
Sep 22 2020 | MTCR | Metacrine, Inc. | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 332,964 | 0 | 2,291,297 | 2 M to 2.3 M (+17.00 %) |
Sep 22 2020 | MTCR | Metacrine, Inc. | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 1,958,333 | 0 | 1,958,333 | 0 to 2 M |
Aug 14 2020 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Buy | J | 0.00 | 14 | 0 | 14 | 0 to 14 |
Aug 14 2020 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Buy | J | 0.00 | 57 | 0 | 256 | 199 to 256 (+28.64 %) |
Jul 28 2020 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Option Exercise | P | 2.25 | 3,151,260 | 7,090,335 | 3,151,260 | |
Jul 28 2020 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Buy | P | 2.25 | 3,151,260 | 7,090,335 | 10,376,936 | 7.2 M to 10.4 M (+43.61 %) |
Jul 13 2020 | NKTX | Nkarta, Inc. | Behbahani Ali | Director | Option Exercise | A | 18.00 | 10,700 | 192,600 | 10,700 | |
Jul 13 2020 | NKTX | Nkarta, Inc. | Behbahani Ali | Director | Option Exercise | A | 18.00 | 10,700 | 192,600 | 10,700 | |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 1,199,976 | 0 | 0 | |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 1,992,238 | 0 | 0 | |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 513,758 | 0 | 0 | |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Buy | P | 17.00 | 588,235 | 9,999,995 | 4,294,207 | 3.7 M to 4.3 M (+15.87 %) |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 1,199,976 | 0 | 3,705,972 | 2.5 M to 3.7 M (+47.88 %) |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 1,992,238 | 0 | 2,505,996 | 513.8 K to 2.5 M (+387.78 %) |
Jul 01 2020 | AKUS | Akouos, Inc. | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 513,758 | 0 | 513,758 | 0 to 513.8 K |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 1.67 | 184,258 | 307,711 | 184,258 | |
Jun 19 2020 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Option Exercise | A | 2.22 | 15,000 | 33,300 | 15,000 | |
Jun 15 2020 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Option Exercise | A | 59.70 | 15,000 | 895,500 | 15,000 | |
Jun 10 2020 | OYST | Oyster Point Pharm ... | Behbahani Ali | Director | Grant | A | 0.00 | 6,600 | 0 | 6,600 | 0 to 6.6 K |
Jun 10 2020 | OYST | Oyster Point Pharm ... | Behbahani Ali | Director | Grant | A | 0.00 | 6,600 | 0 | 6,600 | 0 to 6.6 K |
Apr 13 2020 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Option Exercise | X | 0.00 | 1,500,000 | 1,500 | 0 | |
Apr 13 2020 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Sell | S | 2.66 | 564 | 1,500 | 5,937,998 | 5.9 M to 5.9 M (-0.01 %) |
Apr 13 2020 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Buy | X | 0.00 | 1,500,000 | 1,500 | 5,938,562 | 4.4 M to 5.9 M (+33.79 %) |
Feb 05 2020 | BDTX | Black Diamond Ther ... | Behbahani Ali | Director | Option Exercise | C | 0.00 | 1,422,862 | 0 | 0 | |
Feb 05 2020 | BDTX | Black Diamond Ther ... | Behbahani Ali | Director | Option Exercise | C | 0.00 | 6,565,290 | 0 | 0 | |
Feb 05 2020 | BDTX | Black Diamond Ther ... | Behbahani Ali | Director | Buy | P | 19.00 | 800,000 | 15,200,000 | 3,448,757 | 2.6 M to 3.4 M (+30.20 %) |
Feb 05 2020 | BDTX | Black Diamond Ther ... | Behbahani Ali | Director | Buy | C | 0.00 | 471,800 | 0 | 2,648,757 | 2.2 M to 2.6 M (+21.67 %) |
Feb 05 2020 | BDTX | Black Diamond Ther ... | Behbahani Ali | Director | Buy | C | 0.00 | 2,176,957 | 0 | 2,176,957 | 0 to 2.2 M |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Dec 26 2019 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Option Exercise | P | 0.00 | 900,900 | 0 | 900,900 | |
Dec 26 2019 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Option Exercise | P | 0.67 | 9,009,000 | 5,999,994 | 9,009,000 | |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 29,889,945 | 0 | 0 | |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 29,889,945 | 0 | 0 | |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Behbahani Ali | 10% Owner | Buy | P | 15.00 | 450,000 | 6,750,000 | 4,186,243 | 3.7 M to 4.2 M (+12.04 %) |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Behbahani Ali | 10% Owner | Buy | P | 15.00 | 450,000 | 6,750,000 | 4,186,243 | 3.7 M to 4.2 M (+12.04 %) |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 3,736,243 | 0 | 3,736,243 | 0 to 3.7 M |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 3,736,243 | 0 | 3,736,243 | 0 to 3.7 M |
Jul 19 2019 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Option Exercise | A | 3.66 | 5,625 | 20,588 | 5,625 | |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 0.61 | 234,407 | 142,988 | 234,407 | |
Jun 25 2019 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Buy | P | 3.50 | 2,857,142 | 9,999,997 | 7,225,676 | 4.4 M to 7.2 M (+65.40 %) |
Jun 25 2019 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Buy | P | 3.50 | 2,857,142 | 9,999,997 | 7,225,676 | 4.4 M to 7.2 M (+65.40 %) |
Jun 13 2019 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Option Exercise | A | 43.52 | 15,000 | 652,800 | 15,000 | |
May 13 2019 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Option Exercise | C | 0.00 | 17,099,315 | 0 | 0 | |
May 13 2019 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Buy | P | 10.00 | 1,500,000 | 15,000,000 | 4,438,562 | 2.9 M to 4.4 M (+51.05 %) |
May 13 2019 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Buy | P | 10.00 | 1,000,000 | 10,000,000 | 2,938,562 | 1.9 M to 2.9 M (+51.58 %) |
May 13 2019 | TRVI | Trevi Therapeutics ... | Behbahani Ali | 10% Owner | Buy | C | 0.00 | 1,938,562 | 0 | 1,938,562 | 0 to 1.9 M |
May 09 2019 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Option Exercise | P | 0.00 | 256,700 | 0 | 256,700 | |
May 09 2019 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Option Exercise | P | 1.08 | 3,703,704 | 4,000,000 | 3,703,704 | |
May 09 2019 | RGLS | Regulus Therapeuti ... | Behbahani Ali | 10% Owner | Buy | P | 1.08 | 1,136,704 | 1,227,640 | 2,052,454 | 915.8 K to 2.1 M (+124.13 %) |
Feb 19 2019 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Option Exercise | P | 0.57 | 2,487,067 | 1,406,685 | 2,487,067 | |
Feb 19 2019 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Buy | P | 0.47 | 9,948,269 | 4,688,619 | 34,948,269 | 25 M to 34.9 M (+39.79 %) |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 2.18 | 154,809 | 337,484 | 154,809 | |
Jun 25 2018 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Option Exercise | A | 0.99 | 50,000 | 49,500 | 50,000 | |
Jun 15 2018 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Option Exercise | A | 59.31 | 15,000 | 889,650 | 15,000 | |
Jun 15 2018 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Option Exercise | A | 59.31 | 15,000 | 889,650 | 15,000 | |
May 23 2018 | NVRO | NEVRO CORP | Behbahani Ali | Director | Grant | A | 0.00 | 3,785 | 0 | 5,390 | 1.6 K to 5.4 K (+235.83 %) |
May 23 2018 | NVRO | NEVRO CORP | Behbahani Ali | Director | Grant | A | 0.00 | 3,785 | 0 | 5,390 | 1.6 K to 5.4 K (+235.83 %) |
Feb 12 2018 | GNCA | GENOCEA BIOSCIENCE ... | Behbahani Ali | Director | Option Exercise | A | 0.98 | 25,000 | 24,500 | 25,000 | |
Sep 15 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 8 | 0 | 1,605 | 1.6 K to 1.6 K (+0.50 %) |
Sep 15 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 32 | 0 | 1,597 | 1.6 K to 1.6 K (+2.04 %) |
Jul 03 2017 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 0.75 | 220,788 | 165,591 | 220,788 | |
Jun 02 2017 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Option Exercise | A | 13.62 | 15,000 | 204,300 | 15,000 | |
May 30 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Grant | A | 0.00 | 1,518 | 0 | 1,565 | 47 to 1.6 K (+3,229.79 %) |
Nov 15 2016 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 3 | 0 | 47 | 44 to 47 (+6.82 %) |
Nov 15 2016 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 19 | 0 | 44 | 25 to 44 (+76.00 %) |
Oct 20 2016 | CRSP | CRISPR Therapeutic ... | Behbahani Ali | Director | Option Exercise | A | 14.00 | 30,000 | 420,000 | 30,000 | |
Aug 12 2016 | ADAP | Adaptimmune Therap ... | Behbahani Ali | Director | Option Exercise | A | 1.27 | 184,562 | 234,394 | 184,562 | |
May 20 2016 | NVRO | NEVRO CORP | Behbahani Ali | Director | Option Exercise | A | 63.39 | 3,240 | 205,384 | 3,240 | |
Dec 03 2015 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 3 | 0 | 25 | 22 to 25 (+13.64 %) |
Dec 03 2015 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 22 | 0 | 22 | 0 to 22 |
Jun 01 2015 | NVRO | NEVRO CORP | Behbahani Ali | Director | Option Exercise | A | 50.50 | 4,182 | 211,191 | 4,182 | |
Nov 07 2014 | NVRO | NEVRO CORP | Behbahani Ali | Director | Option Exercise | A | 18.00 | 8,477 | 152,586 | 8,477 |
Page: 1